The North America Hemato Oncology Testing Market was valued at USD 1,375 Million in 2025, and is projected to reach USD 4,120 Million by 2035, expanding at a CAGR of 10.8% during 2024-2035. Key growth drivers include technological advancements and strategic partnerships among leading companies, as well as increasing adoption of advanced molecular diagnostic tests across the region.
The economic impact of tariffs on "North America Hemato Oncology Testing Market".
Market Growth Drivers
Increasing adoption of next-generation sequencing (NGS) in hemato oncology testing is a major growth driver. Companies such as Illumina and Thermo Fisher Scientific are continuously focusing on expanding their NGS product portfolios. This technology offers higher accuracy and speed for detection of genetic mutations associated with blood cancers, leading to better patient management and personalized medicine. The shift towards precision diagnostics not only improves outcomes but also supports clinicians in selecting the most effective therapies for patients.
Strategic collaborations and partnerships are fueling market expansion. For example, in 2023, QIAGEN entered into a partnership with NeoGenomics to jointly develop and commercialize novel testing solutions for hematologic malignancies. These collaborations aim to combine expertise, expand test menus, and streamline regulatory processes, thereby accelerating the availability of advanced diagnostic tests across North America. Such partnerships are expected to enhance healthcare outcomes and expand access to cutting-edge hemato oncology diagnostics.
Market Trends
Growth in liquid biopsy tests is emerging as a prominent trend in the North America hemato oncology testing market. Companies like Guardant Health and Bio-Rad Laboratories have introduced innovative non-invasive testing solutions that allow for regular monitoring of disease progression and therapeutic response in patients with blood cancers. Liquid biopsies provide a safer, more convenient alternative to traditional bone marrow biopsies, fostering higher adoption among clinicians and patients alike.
Integration of artificial intelligence (AI) and machine learning (ML) is transforming diagnostic workflows and interpretation in hemato oncology testing. Leading firms such as Roche and Abbott are introducing AI-powered platforms to enhance the accuracy of data analysis, reduce turnaround times, and offer actionable insights for oncologists. These technologies are rapidly gaining traction, especially in major cancer centers and reference laboratories, and are expected to redefine diagnostic capabilities over the coming years.
Market Opportunities
Rising demand for personalized medicine poses a substantial opportunity for market participants. As awareness increases about the benefits of targeted therapies, companies like Thermo Fisher Scientific are poised to launch new hemato oncology panels that enable tailored treatment plans for individual patients.
Expansion into underpenetrated rural and community healthcare settings in North America represents another key opportunity. With initiatives led by Labcorp, companies are working to bring advanced hemato oncology diagnostics to wider patient populations, enhancing disease detection and patient outcomes.
North America Hemato Oncology Testing Market Revenue (USD Million), 2020-2035
The chart depicts the progressive growth of the North America Hemato Oncology Testing Market from 2020 to 2035. Starting at USD 650 Million in 2020, the market demonstrates steady expansion due to increasing prevalence of blood cancers, advancements in diagnostic technology, and greater awareness about early detection. The market is forecasted to reach USD 1,375 Million by 2025, maintaining an upward trajectory to reach approximately USD 4,120 Million by 2035. Throughout this period, investments in R&D, introduction of novel tests, and rising adoption in both clinical and research settings are expected to drive robust double-digit CAGR, indicating significant opportunities for both established and emerging players.
North America Hemato Oncology Testing Market by Region Share (%), 2025
The pie chart illustrates the regional market share distribution in 2025. The United States dominates the North American hemato oncology testing market, accounting for 72% of market share, driven by its advanced healthcare infrastructure and the presence of key industry players. Canada follows with 18%, benefiting from increased healthcare investments and rising adoption of molecular diagnostics. Mexico holds 7% share, attributed to improvements in healthcare access and cancer awareness. The remaining 3% is shared between the Caribbean and Rest of North America, where adoption of advanced testing methods is gradually increasing. This distribution highlights the significant market potential across all North American regions, with the US expected to maintain its leading position through the forecast period.
Recent Developments
In February 2024, Illumina launched a new hematologic cancer panel designed to enhance detection of rare mutations in leukemia and lymphoma. This next-generation sequencing panel features improved sensitivity and rapid turnaround time, receiving positive feedback from major cancer centers across the United States. The initiative demonstrates Illumina’s continued commitment to providing advanced tools that support precision oncology and personalized medicine.
In March 2024, QIAGEN and NeoGenomics announced their collaboration to co-develop a range of novel molecular tests for blood cancers. This partnership aims to streamline the regulatory process and broaden access to NGS-based diagnostic solutions across North America. The joint development strategy will support hospitals and labs in offering comprehensive testing services for hematologic malignancies, further strengthening their foothold in the market.
In May 2024, Roche received FDA breakthrough device designation for its AI-powered digital pathology solution designed for rapid diagnosis of hematologic malignancies. The new system leverages deep learning algorithms to interpret biopsy slides with high accuracy, reducing diagnostic errors and turnaround time. The advancement is expected to set a benchmark for technologically enhanced diagnostics in hemato oncology testing.
Press Releases